Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 450Stomach Neoplasms 295Rectal Neoplasms 271Colonic Neoplasms 192Pancreatic Neoplasms 177Neoplasm Metastasis 110Esophageal Neoplasms 88Neoplasms 68Carcinoma, Hepatocellular 60Adenocarcinoma Of Esophagus 47Cholangiocarcinoma 46Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 38Gallbladder Neoplasms 31Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 25Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 18Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

xaliproden 2Oxygen 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 12,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paresthesia × Oxaliplatin × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡